RxDoctor Payments Data

Trinh Duong Pham, MD

Internal Medicine · Wesley Chapel, FLNPI 1174028047

Payments from drug & device makers

$3,540in general payments, 2019–2025

Across 166 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$774
  • Novo Nordisk$731
  • Lilly USA, LLC$511
  • Pfizer$350
  • Stryker$135
  • Biohaven Pharmaceutical Holding Company Ltd.$133
  • plus $907 from 17 others

What the payments were for

  • Food & beverage$3,526100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,540 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$86,872
Medicare patients
215
Services billed
954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$39,594
TrulicityDulaglutide26$31,335
OzempicSemaglutide24$25,336
MounjaroTirzepatide23$24,461
FarxigaDapagliflozin Propanediol14$11,396
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide76$2,681
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med71$1,913
Rosuvastatin Calcium115$1,908
SynthroidLevothyroxine Sodium11$1,370
Levothyroxine Sodium115$1,062
Amlodipine-ValsartanAmlodipine Besylate/Valsartan18$858
Atorvastatin Calcium127$816
Gabapentin38$814
Metformin Hcl ErMetformin Hcl62$696
Olmesartan Medoxomil60$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$511$55,79649 claims
Boehringer IngelheimJardiance$118$39,59425 claims
Novo NordiskOzempic$731$25,33624 claims
AstraZenecaFarxiga$57$11,39614 claims
AbbVieSynthroid$774$1,37011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →